AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Bone Marrow TransplantationTransplantation, HomologousBone MarrowGraft vs Host DiseaseBone Marrow CellsHematopoietic Stem Cell TransplantationTransplantation, AutologousTransplantation ConditioningHistocompatibilityWhole-Body IrradiationTransplantation ChimeraLeukemiaTissue DonorsHistocompatibility TestingBone and BonesGraft SurvivalAnemia, AplasticHematologic NeoplasmsLiver TransplantationSevere Combined ImmunodeficiencyBusulfanLymphocyte DepletionHLA AntigensBone Marrow PurgingCyclophosphamideRecurrenceTreatment OutcomeHematopoietic Stem CellsTransplantation, IsogeneicGraft vs Leukemia EffectLeukemia, Myeloid, AcuteBone Marrow DiseasesImmunosuppressive AgentsKidney TransplantationRemission InductionStem Cell TransplantationT-LymphocytesGraft RejectionHematopoiesisPrecursor Cell Lymphoblastic Leukemia-LymphomaCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte TransfusionMice, Inbred C57BLRadiation ChimeraHepatic Veno-Occlusive DiseaseBone Marrow ExaminationAcute DiseaseTime FactorsTransplantation ImmunologyPeripheral Blood Stem Cell TransplantationRetrospective StudiesHaploidyCord Blood Stem Cell TransplantationBone RemodelingLeukemia, MyeloidBone Marrow NeoplasmsImmunosuppressionGraft vs Host ReactionLymphoma, Non-HodgkinHaplotypesLeukocyte TransfusionHeart TransplantationSurvival AnalysisMyelodysplastic SyndromesHematologic DiseasesAntilymphocyte SerumDisease-Free SurvivalSurvival RateChimeraColony-Forming Units AssayFollow-Up StudiesGranulocyte Colony-Stimulating FactorLung TransplantationAntigens, CD34CyclosporineLiving DonorsGraft vs Tumor EffectActuarial AnalysisBone DensityCytomegalovirus InfectionsAntineoplastic Combined Chemotherapy ProtocolsOrgan TransplantationMyeloablative AgonistsNuclear FamilyFetal TherapiesCarmustineSiblingsCytarabineCell DifferentiationPancytopeniaUnrelated DonorsMelphalanLeukocyte CountChimerismBone ResorptionSpleenFlow CytometryMice, Inbred BALB CMultiple Myeloma
GVHDDonorsPeripheral blood stem cell transplantChemotherapyHaematopoietic stem cell transplantHematologyUnderwentHematopoietic stem cellGraftOutcomesObserved in allogeneicAcuteHuman leukocyClinicalAllogeneic hematopoietic cellSurvivalComplications2022Achieved complete remission2021AspirationMalignanciesCord blood2020HematologicalDonor transplantationStem cellsDiseasesLong-term survivorsRelapseBloodLeukemicRecipientsEfficacyOrganMortalityInduceReconstitutionCurativeDisordersMedian ageRepopulateBiopsyPBSCStromal
GVHD15
  • In addition to complications seen from exposure to chemotherapy and radiation, patients undergoing allogeneic transplantation can experience unique late effects secondary to graft versus host disease (GVHD) and autoimmunity. (medscape.com)
  • Causes of death were related to relapse of the underlying cancer, development of a second cancer, chronic GVHD, or transfusion-acquired viral infection. (medscape.com)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • After HSC transplantation both GvL and GvHD develop. (wikipedia.org)
  • The interconnection of those two effects can be seen by comparison of leukemia relapse after HSC transplantation with development of GvHD. (wikipedia.org)
  • There are some strategies to suppress the GvHD after transplantation or to enhance GvL but none of them provide an ideal solution to this problem. (wikipedia.org)
  • When using non-depleted T-cell transplant, cyclophosphamide is used after transplantation to prevent GvHD or transplant rejection. (wikipedia.org)
  • Other strategies currently clinically used for suppressing GvHD and enhancing GvL are for example optimization of transplant condition or donor lymphocyte infusion (DLI) after transplantation. (wikipedia.org)
  • Nonetheless, consolidative allo-HSCT is not recommended for all patients because it will increase the economic burden and bring risk of severe toxicity, such as graft-versus-host disease (GVHD). (biomedcentral.com)
  • Adult patients (age ≥ 18) eligible for and planned to undergo a standard-of-care reduced intensity conditioning (RIC) HLA-matched related or related haploidentical allogeneic stem cell transplant using PTCY-based GVHD prophylaxis. (survivornet.com)
  • Despite prophylactic treatment of the patients with immunosuppressive drugs after allo-HSCT, GvHD is still associated with non-relapse mortality (NRM) and contributes around 25% of NRM. (frontiersin.org)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • The 3-year probability of total chronic graft-versus-host disease (GVHD) was 21.4% and 34.1% in the haploidentical and HLA-matched HSCT groups, respectively ( P =0.526). (blood-genomics.com)
  • Graft-versus-host disease (GVHD) and infections are the major obstacles of HSCT, and their close relationship has been suggested. (ashpublications.org)
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
Donors11
  • Allogeneic bone marrow transplantation, as we understood it, allows saving lives, but cannot take place without donors. (longdom.org)
  • If the geno-identical transplantation is impossible, we will direct ourselves towards the national and international register donors of bone marrow. (longdom.org)
  • This is a single arm pilot study using TCR alpha/beta+ T cell-depleted peripheral blood stem cells (PBSC) from closely matched unrelated donors or partially matched/haploidentical related donors for hematopoietic stem cell transplant (HSCT) in patients with acquired and inherited bone marrow failure (BMF) syndromes. (sparkcures.com)
  • Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors). (frontiersin.org)
  • Donors included matched sibling donors (MSD), matched unrelated donors (MUD), mismatched unrelated donors (MMUD) and haploidentical/mismatched related donors (MMRD). (biomedcentral.com)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • In the analysis, the investigators included 200 patients made up of 63 allogeneic-HSCT recipients, 74 autologous-HSCT recipients, and 63 HSCT donors. (contagionlive.com)
  • The study found that rates of latent tuberculosis were 17% in all-HSCT recipients, 24% in auto-HSCT, and 39% in donors. (contagionlive.com)
  • With transplant rates ranging from 0.1 to 1001 per 10 million inhabitants, more HSCTs were registered from unrelated 16 433 donors than related 15 493 donors. (unisg.ch)
  • For patients lacking matched sibling donors, haploidentical donors are an option. (blood-genomics.com)
  • We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. (biomedcentral.com)
Peripheral blood stem cell transplant2
Chemotherapy8
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • The blood cells are harvested from the donor and stored, and then the sickle cell disease patient is given high doses of chemotherapy to get rid of all the remaining blood cells in the bone marrow in order for them to be able to receive the healthy donated cells. (reachmd.com)
  • Furthermore, r/r B-ALL patients may develop severe organ damage or infection after aggressive chemotherapy and, hence, be precluded from allo-HSCT. (biomedcentral.com)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • Approximately one-third of children with acute myeloid leukemia (AML) experience disease relapse despite risk-adapted intensive multiagent chemotherapy with or without hematopoietic cell transplantation (HCT) [ 1 ]. (biomedcentral.com)
  • Recent advances in flow cytometric and molecular measurable residual disease detection have further enhanced modern risk-stratified approaches to chemotherapy and allocation to allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) when indicated. (haematologica.org)
  • Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
  • The superior clinical outcomes of allogeneic SCT versus chemotherapy alone as post-remission treatment could be related to the graft-versus-leukemia (GVL) effects of recovered donor T cells. (biomedcentral.com)
Haematopoietic stem cell transplant1
  • After undergoing an allogeneic haematopoietic stem cell transplantation (alloHCT), patients need intensive physiological and psychological rehabilitation. (mdpi.com)
Hematology1
  • We analyzed patient-reported QoL, CF, and symptoms of depression and anxiety in patients with primary or secondary AML who received their 1st allo-HSCT with TBI-based protocols at the Department of Hematology of the University Hospital Regensburg between 1999 and 2017. (biomedcentral.com)
Underwent5
  • The final sample consisted of 35 records patients aged between 2 and 18 years old who underwent HSCT from February 2008 to December 2015 and who presented the data necessary for the study. (bvsalud.org)
  • For the study, the investigators conducted a retrospective analysis of clinical data from patients who underwent a HSCT between January 2010 and December 2016 at the Salvador Zubirán National Institute of Health Sciences and Nutrition. (contagionlive.com)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT ( n =68) or human leukocyte antigen (HLA)-matched HSCT ( n =51). (blood-genomics.com)
  • This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who received unmanipulated haploidentical allografts. (biomedcentral.com)
Hematopoietic stem cell2
  • Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. (contagionlive.com)
  • ECIL-6 guidelines recommend quantitative PCR of whole blood, plasma, or serum to screen for EBV DNA in allogeneic hematopoietic stem cell transplant (HSCT) recipients and to monitor EBV DNA-emia. (medscape.com)
Graft11
  • Graft-versus-tumor effect (GvT) appears after allogeneic hematopoietic stem cell transplantation (HSCT). (wikipedia.org)
  • Graft-versus-host disease Hematopoietic stem cell transplantation Thompson LF, Tsukamoto H, Chernogorova P, Zeiser R (January 2013). (wikipedia.org)
  • However, since there are transplant-related risks such as graft versus host disease and life-threatening infection, as well as organ toxicity, one could likely not be transplanted if their sickle cell disease was not under really good control or if they had minimal disease manifestations. (reachmd.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is applied successfully to the treatment of many hematopoietic malignancies, but remains limited by severe acute graft-versus-host-disease (aGvHD). (frontiersin.org)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • 2 Most subsequent transplantations in IEM have been for Hurler syndrome (MPSIH), and it remains the most common IEM for which HSCT is indicated and performed and about which most is understood in terms of factors determining both graft and disease outcome. (ashpublications.org)
  • 345 Prophylactic Tocilizumab Decreases Incidence of Acute Graft-Versus-Host Disease Following Alpha/Beta T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation in Children and Young Adults. (ucsf.edu)
  • We demonstrated that iPSC-derived MSC treatment leads to significant increases in hTSG-6 protein, followed by an upregulation of mouse Tregs and IL-5, IL-10, and IL-15 cytokines, which augments graft microvascular blood flow and oxygenation, and thereby maintained a healthy airway epithelium and prevented the subepithelial deposition of collagen at d90 post transplantation. (biomedcentral.com)
  • Existing immunosuppressive drugs for organ transplantation may achieve sufficient immunosuppression to prevent organ rejection or limit autoreactivity, but they are typically not successful in achieving long-term survival of the graft or preventing progression of fibrosis and chronic rejection [ 3 ]. (biomedcentral.com)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
  • 2015/2021 Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes. (ulisboa.pt)
Outcomes6
  • So what are the realities and clinical outcomes associated with hematopoietic stem cell transplantation in sickle cell disease? (reachmd.com)
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
  • Over the last years, transplantation outcomes have improved in this group of patients as the factors that predicted for poor transplantation outcomes were understood and addressed. (ashpublications.org)
  • Improved outcomes of transplantation have been reported when performed before the development of HLH, thus it is important to quickly differentiate patients that present with the childhood form of disease and to prematurely enroll them into a transplantation protocol. (biomedcentral.com)
  • Finally, patients with a first relapse of AML (without or with prior HSCT) clearly represent a different disease population from patients with primary chemorefractory disease or from those in second or greater relapse who collectively experience highly different outcomes. (haematologica.org)
  • Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases. (cdc.gov)
Observed in allogeneic1
  • Major increases were observed in allogeneic, haploidentical HSCT and, to a lesser extent, in cord blood transplantation. (unisg.ch)
Acute10
Human leukocy2
  • The work of Jean Dausset, whose discovery of the human leukocyte antigen (HLA) system revolutionized our understanding of tissue compatibility for transplantation (Dausset J, 1958). (revistadehematologia.org.mx)
  • The first evidence for the therapeutic effectiveness of natural killer (NK) cells in AML was established in a study of 57 adult patients, in which none of the 20 individuals who received haploidentical cell transplantation from a killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donor experienced disease relapse [ 2 ]. (biomedcentral.com)
Clinical11
  • Methods: The General situation, clinical manifestations and chromosome breakage test and genetic test results of 107 pediatric FA cases registered in the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) and the Chinese Children Blood and Marrow Transplantation Registry Group (CCBMTRG) from August 2009 to January 2022 were analyzed retrospectively. (bvsalud.org)
  • To characterize the clinical and epidemiological profile of children and adolescents submitted to HSCT at a referral service in the state of Rio Grande do Norte. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • These methods and results can help us to better understand immune reconstitution following hematopoietic cell transplantation, leading to future studies on the clinical application of adoptive T-cell therapies. (nature.com)
  • Recent clinical data indicate that patients with complex karyotypes, adverse genes, and high pre-infusion minimal residual disease (MRD) by flow cytometry in the bone marrow, were at high risk of relapse after CAR T-cell therapy. (biomedcentral.com)
  • Allo-HSCT provides optimal clinical benefit in patients with MRD-negative complete remission, typically within three months after CAR T-cell therapy. (biomedcentral.com)
  • Herein, we summarize the clinical data on consolidative allo-HSCT after anti-CD19 CAR T-cell therapy, as well as the potential factors associated with allo-HSCT benefit. (biomedcentral.com)
  • If there is no clinical evidence of a change in cardiovascular function from the time of pre-transplantation ECHO (per FACT standards should be performed within 6 weeks of stem cell infusion), then there is no need to repeat it. (survivornet.com)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The successful application of HSCT for diseases such as leukemia, lymphoma, myeloma, and inherited blood disorders underscored its broad applicability in clinical practice (Snowden et al. (revistadehematologia.org.mx)
  • Many of the clinical complications of PV relate directly to the increase in blood viscosity associated with red cell mass elevation and indirectly to the increased turnover of red cells, leukocytes, and platelets with the attendant increase in uric acid and cytokine production. (basicmedicalkey.com)
Allogeneic hematopoietic cell2
  • Cytomegalovirus reactivation is still a critical concern following allogeneic hematopoietic cell transplantation, and cellular immune reconstitution of cytomegalovirus-specific cytotoxic T-cells is necessary for the long-term control of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation. (nature.com)
  • Forlanini F, Zinter MS, Dvorak CC, Bailey-Olson M, Winestone LE, Shimano KA, Higham CS, Melton A, Chu J, Kharbanda S. Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children. (ucsf.edu)
Survival2
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
Complications5
  • If one of the brothers and sisters is compatible, we speak about geno-identical allogeneic transplantation having the advantage of reducing the complications post-transplantation. (longdom.org)
  • Under the slogan of "cure without late complications," we have successfully minimized treatment-related late complications with reduced intensity conditioning (RIC) for hematopoietic stem cell transplantation and immunotherapy, which have smaller side effects. (opho.jp)
  • Allo-hSCT is estimated to reduce the risk of leukemia relapse to half, but with significant risk for treatment-related complications. (cancercentrum.se)
  • The study suggests that haploidentical HSCT shows comparable OS, LFS, and GRFS to HLA-matched HSCT in pediatric patients with acceptable complications, and can therefore be recommended as an effective alternative for this population. (blood-genomics.com)
  • Dr. Dora Ho specializes in infection complications in immunocompromised patients, such as those with bone marrow transplant, solid organ transplant, cancers and other forms of immunodeficiency. (stanford.edu)
20221
  • 2020/2022 CMV infection and CMV-specific T-cell reconstitution in unrelated donor allo-HSCT after in vivo T-cell depletion with ATG: a comparative study of prophlylaxis with letermovir versus standard of care preemptive. (ulisboa.pt)
Achieved complete remission1
  • Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. (oncotarget.com)
20212
  • 2021). Twenty years later, in 1980, Ricardo Sosa and his coworkers at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán conducted and published another HSCT (Sosa-Sánchez et al. (revistadehematologia.org.mx)
  • 2021/2024 Generation and in-depth characterization of antigen-specific regulatory T cells to be applied in allogeneic hematopoietic stem transplantation. (ulisboa.pt)
Aspiration2
  • Bone marrow aspiration is carried out by a puncture on the level of the sternum or the posterior iliac peaks under local anesthesia by the doctor. (longdom.org)
  • Bone marrow aspiration is performed after hematopoietic recovery, or day 28 at the latest. (cancercentrum.se)
Malignancies2
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (longdom.org)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
Cord blood3
  • Source of stem cells were peripheral blood, bone marrow or cord blood. (biomedcentral.com)
  • The use of umbilical cord blood (UCB) has been steadily increasing, and UCB transplantation (UCBT) currently accounts for one-third of all allogeneic HCTs. (apbmt.org)
  • 1999). First identified and isolated from the bone marrow (BM), MSCs can now be expanded from a variety of other tissues including adipose tissue (AT), umbilical cord blood (UCB), skin, tendon, muscle, and dental pulp (Im et al. (pdffox.com)
20203
  • The total number of HSCT was 30 in 2020. (opho.jp)
  • Of the 21 allogeneic HSCT in 2020, 20 were transplanted using RIC. (opho.jp)
  • The total number of autologous and allogeneic HSCT was 1043 between 1991 and the end of 2020. (opho.jp)
Hematological1
  • In addition, we perform HLA-haploidentical HSCT, including HCT with post-transplant cyclophosphamide (PTCY) for non/less-malignant hematological diseases, and T-cell replete HSCT for advanced leukemia. (opho.jp)
Donor transplantation1
Stem cells4
Diseases3
Long-term survivors3
  • In a study from the United States, long-term survivors of pediatric bone marrow transplantation followed in the Bone Marrow Transplant Survivors Study were compared with survivors of childhood cancer treated without bone marrow transplant from the Childhood Cancer Survivor Study. (medscape.com)
  • These data reinforce the need for marked vigilance in ensuring proper screening and management of long-term survivors of bone marrow transplantation. (medscape.com)
  • Our data indicate that CF of long-term survivors upon TBI-based allo-HSCT is not impaired, even in the presence of active cGvHD. (biomedcentral.com)
Relapse2
  • High pre-lymphodepletion lactate dehydrogenase, low pre-lymphodepletion platelet count, absence of fludarabine in lymphodepletion, persistent leukemic sequence by high throughput sequencing in bone marrow after CAR T-cell infusion, and early loss of CAR T cells have also been linked to relapse after CAR T-cell therapy. (biomedcentral.com)
  • The combination of CAR T-cell therapy and allo-HSCT has been suggested to reduce the relapse rate of leukemia. (biomedcentral.com)
Blood3
  • Bone marrow is the place for the production of the hematopoietic cells which differentiate in to three groups: red blood cells, white blood cells and platelets. (longdom.org)
  • Storage of bone marrow or blood leukemic cells in biobanks is strongly recommended. (cancercentrum.se)
  • Further, the HSCT was peripheral blood in 83 patients, bone marrow in 21, and primed-bone marrow in 21 patients. (contagionlive.com)
Leukemic1
  • In all patients that might become considered for intensive treatment, the AML diagnosis should be based on morphologic and immunophenotypic features of bone marrow aspirates as well as on genetic characteristics of the leukemic blasts. (cancercentrum.se)
Recipients1
  • To our knowledge, this is the first study that evaluates the prevalence of LTBI among HSCT recipients in a Latin American country where TB is endemic," the investigators wrote. (contagionlive.com)
Efficacy1
  • The mechanism of transplantation efficacy in X-ALD is not by cross-correction of enzyme-deficient host cells by secreted enzyme, so this condition will be discussed separately at the end of this review. (ashpublications.org)
Organ1
Mortality2
  • Transplant-related mortality (TRM), although steadily declining, still remains a challenge [ 2 ]. (longdom.org)
  • 1980). As with many countries embarking on this procedure, there were challenges related to transplant-related morbidity and mortality. (revistadehematologia.org.mx)
Induce2
Reconstitution1
  • The main research focus of our laboratory is the study of immune reconstitution after hematopoietic stem cell transplantation (HSCT) in humans and the development of strategies that modulate immune responses and tolerance post-transplant. (ulisboa.pt)
Curative3
Disorders3
  • HSCT, there are still some factors that need to be metabolism disorders, among others. (bvsalud.org)
  • To assess the safety of donor natural killer (NK) cell infusion after HLA-mismatched/haploidentical allogeneic hematopoietic stem cell transplantation from a familial donor in patients with advanced malignant disorders. (bioseek.eu)
  • Other IEMs treated by HSCT include other mucopolysaccharide disorders such as Maroteaux Lamy syndrome (MPSVI), other lysosomal storage disorders (LSDs), and the peroxisomal disorder X-linked adrenoleukodystrophy (X-ALD). (ashpublications.org)
Median age1
Repopulate2
  • NK cells are within the first cells to repopulate host's bone marrow which means they play important role in the transplant engraftment. (wikipedia.org)
  • The cells are remarkable in that they can find their way into the recipient's bone marrow, where they begin to divide and repopulate the patient's bone marrow as his or her own. (reachmd.com)
Biopsy1
  • A bone marrow aspirate and biopsy provide no specific diagnostic information because these may be normal or indistinguishable from ET or PMF. (basicmedicalkey.com)
PBSC1
  • In cases of unrelated HCT, PBSC transplantation (PBSCT) still comprises only a very small percentage, which reflects the fact that unrelated PBSCT did not come into use in Japan until 2010. (apbmt.org)
Stromal1
  • Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)